Skip to main content
Log in

Investigations on the adsorbents for uremic middle molecular toxins (II)

Influences of crosslinking agent chain length on the adsorption capacities of crosslinked chitosan adsorbents

  • Published:
Science in China Series B: Chemistry Aims and scope Submit manuscript

Abstract

Chitosan resins, which clinically served as adsorbents in hemo perfusion therapy, were prepared with reversed-phase suspension methodology using three differently structured crosslinking agents, methanal, glyoxal and glutaraldehyde. And the glyoxal and glutaraldehyde crosslinked chitosan resins were reduced with NaBH4 afterwards. By analyzing the results from FTIR and SEM, it was found that the reduction treatment to the adsorbents efficiently improved the chemical stability of these chitosan resins, and the shifts in crosslinking agents exerted influences over the morphologies of the adsorbents obviously. After being put to use in the adsorption tests upon some model uremic middle molecular toxins and BSA in vitro, all three adsorbents demonstrated a fairly realistic adsorption capability to the model toxins but little to BSA. And the adsorption process reached the equilibrium in a clinically qualified short time. But the adsorption capacities of these adsorbents to the model toxins were quite different. It had been found that with the growing of fatty chain length of crosslinking agent, these adsorbents showed a gradually increased adsorption capacity to the model toxins, and the glutaraldehyde crosslinked chitosan resin behaved best.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Yu, Z. Y., Blood Purification, 2nd ed., Beijing: Modern Publishing House, 1994, 273.

    Google Scholar 

  2. Babb, A., Popovich, R., Christopher, T. et al., The genesis of the square meter-hour hypothesis, Trans. Am. Soc. Artif Intern. Organs., 1971, 17: 81.

    CAS  Google Scholar 

  3. Babb, A., Farrell, R., Uvelli, D. et al., Hemodialyzer evaluation by examination of solute molecular spectra, Trans. Am. Soc. Artif. Intern. Organs., 1972, 18: 98.

    CAS  Google Scholar 

  4. Babb, A., Strand, H., Uvelli, D. et al., Quantitative description of dialysis treatment: A dialysis index, Kidney Int., 1975, 5: 23.

    Google Scholar 

  5. Scribner, G. E., The search for the uremic toxin(s), Kidney Int., 1975, 7: 270–274.

    Google Scholar 

  6. Giovanetti, S., Barsotti G, Uremic intoxication, Nephron., 1975, 14: 123.

    Article  Google Scholar 

  7. Zimmerman, L., Jörnvall, H., Bergström, J. et al., Characterization of middle molecule compounds, Int. J. Artif. Organs (Suppl.), 1980, 4:33.

    Google Scholar 

  8. Yuan, Z., Zhang, J., Zhao, F. Z. et al., Isolation and preliminary characterization of properties of middle molecules from sera of uremic patients, Chemical Journal of Chinese Universities (in Chinese), 1989, 10: 401.

    Google Scholar 

  9. Yuan, Z., He, B. L., The proposal and advances of middle molecule hypothesis, Ion Exchange and Adsorption (in Chinese), 1997, 13(1): 98.

    CAS  Google Scholar 

  10. Chu, J. G, Yuan, Z., Teng, X. L. et al., Separation and analysis of middle molecular substances from both of uremic and normal sera, Science in China, Series B (in Chinese), 2000, 30(3): 250.

    Google Scholar 

  11. Fürst, P., Bergström, J., Gordon, A. et al., Separation of peptides of “middle molecular” weight from biological fluids of patients with uremia, Kidney Int., 1975, 7: 272.

    Google Scholar 

  12. Zimmerman, L., Baldesten, A., Bergström, J. et al., Isotachophoretic separation of middle molecule peptides in uremic body fluids, Clin. Nephrol., 1980, 13: 183.

    CAS  Google Scholar 

  13. Mabuchi, H., Nakahashi, H., Medium-sized peptides in the blood of patients with uremia, Nephrol., 1983, 33: 232.

    CAS  Google Scholar 

  14. Mabuchi, H., Nakahashi, H., Profiling of urinary medium sized peptides in normal and uremic urine by high-performance liquid chromatography, J. Chromatogr, 1982, 233: 107.

    Article  CAS  Google Scholar 

  15. Mabuchi, H., Nakahashi, H., Analysis of middle molecular peptides in normal and uremic body fluids by high-performance gel chromatography, J. Chromatogr., 1981, 224: 322.

    Article  CAS  Google Scholar 

  16. Flanagan, R. W. J., Murphy, R. F., Buchanan, K. D., Circulating forms of glucagon and related peptides in normal subjects and uraemic patients, Biochem. Soc. Transt., 1980, 8: 426.

    CAS  Google Scholar 

  17. Matthaei, D., Ludwig-Köln, H., Kramer, P. et al., Changes of plasma hormone levels in hemofiltration, Int. J. Artif. Organs, 1983, 6:21.

    CAS  Google Scholar 

  18. Ehrlich, R. W., Holland, F., Turnham, T. et al., Osmotic concentration of polypeptides from hemofiltrate of uremic patients, Clin. Nephrol., 1980, 14: 31.

    CAS  Google Scholar 

  19. Menyhart, J., Grof, J., Many hitherto unknown peptides are principal constituents of uremic “middle molecules”, Clin. Chem., 1981, 27: 1712.

    CAS  Google Scholar 

  20. Wang, S. X., Wu, J. P., Nephrology, Beijing: People’s Health Publishing House, 1987, 740.

    Google Scholar 

  21. Chu, J. G, Investigations on the separation, characterization and toxicity of middle molecular substances, Doctoral Dissertation, Nankai University, 2000, 108.

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, H., Yuan, Z., Liu, X. et al. Investigations on the adsorbents for uremic middle molecular toxins (II). Sc. China Ser. B-Chem. 44, 457–464 (2001). https://doi.org/10.1007/BF02880674

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02880674

Keywords

Navigation